Wegovy 7.2 mg is in Singapore's registered label. The product information says that, if needed, for weight management in patients with obesity, the dose can be increased to 7.2 mg once weekly after at least four weeks on 2.4 mg, and lowered back to 2.4 mg if no additional improvement in body weight is seen (NDF). In Singapore it is given as three 2.4 mg injections, one after another. It is an optional step above the 2.4 mg maintenance dose, not a starting dose, and whether it suits a person is the prescribing doctor's decision. This article covers what the label says, what the STEP UP trial found, what the dose would and would not change for someone starting or already on a GLP-1 medication with another doctor, and where it sits in a programme designed to end.
Availability in Singapore. This medicine is registered with Singapore's Health Sciences Authority, and its registered indication includes weight management. Which medicine suits a particular person, if any does, is decided by the doctor who assesses them.
Estimand: the question a trial's headline number answers. The treatment-policy (treatment-regimen) estimand is the average effect regardless of adherence; the efficacy estimand is the effect if everyone had adhered (Novo Nordisk Singapore).
What does the Singapore label say about 7.2 mg?
It says the dose can be raised to 7.2 mg once weekly after at least four weeks on 2.4 mg, if needed, for weight management in patients with obesity, and to lower it to 2.4 mg if there is no additional clinical improvement in body weight (NDF).
| Label point (section 4.2) | What it says |
|---|---|
| When 7.2 mg can be reached | After a minimum of 4 weeks on the 2.4 mg dose, if needed |
| For whom | Weight management in patients with obesity |
| How the 7.2 mg dose is given | Three doses of 2.4 mg, one after each other |
| If there is no additional improvement | Lower the dose to 2.4 mg once weekly |
| Adolescents from age 12 | Weekly doses above 2.4 mg are not recommended |
Source: NDF, read 9 October 2026. The same text is on all ten registered Wegovy product pages.
Treatment starts at 0.25 mg and builds over 16 weeks to 2.4 mg, so 7.2 mg is only ever a later step. "Obesity" in section 4.1 of the label means a BMI of 30 kg/m² or above. That is the label's number, not GetLean's eligibility criteria, which are set out in am I eligible.
How did the 7.2 mg dose reach Singapore's label?
On the existing registrations, not on a new product. The ten Wegovy products on the register were approved in February and March 2023, and none is named for a 7.2 mg dose (HSA register). HSA's list of approvals records a major variation to those registrations on 23 June 2026; it prints the indication wording, not the dosing section, so it does not say which change that was (HSA approvals). On 8 July 2026 the registrant announced that the Singapore label had been updated with STEP UP evidence (Novo Nordisk Singapore).
Registered is not the same as in stock. None of the sources read for this page says whether the dose is held by pharmacies or clinics in Singapore.
How does the Singapore version differ from the US and UK versions?
Singapore builds 7.2 mg from three 2.4 mg injections; other regulators have approved a product made for it. The FDA approved a 7.2 mg weekly dose on 19 March 2026 with its own labelling, under the name Wegovy HD (FDA). The UK approved a single-dose 7.2 mg pen on 14 April 2026 and the EU on 15 July 2026 (Novo Nordisk report). No such pen and no product called Wegovy HD is on Singapore's register or among HSA's approvals to 27 August 2026, checked 9 October 2026 (HSA register; HSA approvals). An approval elsewhere does not register a medicine here.
What did the STEP UP trial find?
STEP UP, a phase 3b trial funded by Novo Nordisk, randomised 1,407 adults with a BMI of 30 or above and without diabetes, at 95 sites in 11 countries, to semaglutide 7.2 mg, 2.4 mg or placebo, each with a lifestyle intervention, for 72 weeks (Wharton 2025).
| Arm | Adults | Mean weight change at 72 weeks |
|---|---|---|
| Semaglutide 7.2 mg | 1,005 | −18.7% |
| Semaglutide 2.4 mg | 201 | −15.6% |
| Placebo | 201 | −3.9% |
STEP UP, phase 3b, treatment-policy estimand. 7.2 mg versus 2.4 mg: −3.1 percentage points (95% CI −4.7 to −1.6). Mean starting BMI 39.9. Individual results vary and are not guaranteed (Wharton 2025).
The registrant's announcements quote 20.7% for 7.2 mg. That is the efficacy estimand; the same announcement gives the 18.7% above as the treatment-regimen figure (Novo Nordisk Singapore).
On 7.2 mg, 2.4 mg and placebo respectively, stomach and gut adverse events were reported by 70.8%, 61.2% and 42.8%; dysaesthesia, a group of altered skin sensations, by 22.9%, 6.0% and 0.5%; and serious adverse events by 6.8%, 10.9% and 5.5% (Wharton 2025).
What would 7.2 mg change for someone starting treatment?
Nothing in the first months. Treatment begins at 0.25 mg and reaches 2.4 mg over 16 weeks; 7.2 mg is an optional step after at least four weeks at 2.4 mg (NDF). The question of a higher dose belongs to a later review, and the decision is the prescribing doctor's. How GLP-1 dose titration works sets out the first 16 weeks.
What would it change, and not change, for someone already on a GLP-1 with another doctor?
It would change the dose and how it is given. It would not change who decides, or the plan for how treatment ends.
What it would change
- The dose: 7.2 mg once weekly instead of 2.4 mg, given in Singapore as three injections (NDF).
- The trial side-effect picture: more stomach and gut events and more dysaesthesia than on 2.4 mg (Wharton 2025).
What it would not change
- The conditions in the label: tied to patients with obesity who have spent at least four weeks on 2.4 mg, with a step back to 2.4 mg if there is no additional improvement (NDF).
- Who decides: the medicine and dose are chosen by the doctor who assesses the person.
- The medicine: 7.2 mg is a semaglutide dose and says nothing about tirzepatide (Mounjaro). STEP UP compared 7.2 mg with 2.4 mg and placebo; Wegovy vs Mounjaro covers the head-to-head trial of tirzepatide and semaglutide.
A person moving to a new doctor brings their history with them. At GetLean, Dr Quek reviews that history before anything changes, and suitability is decided at the consultation rather than by a number. The medicine and dose, if any, are then his decision at that review.
Where does a higher dose sit in a programme designed to end?
At GetLean, the programme is designed to end: our philosophy is that GLP-1 medication should act as a catalyst — not something to depend on indefinitely. GetLean is a doctor-led GLP-1 weight-loss programme in Singapore, designed to end from day one. Someone starting has the exit planned from the first consultation; someone already on a GLP-1 with another doctor has their history reviewed before anything changes.
The label itself moves the dose in both directions: it lowers to 2.4 mg if there is no additional improvement, and allows delaying escalation or lowering to the previous dose when stomach symptoms are significant (NDF). The reason for a planned exit does not depend on the dose. In the STEP 1 extension, adults stopped semaglutide 2.4 mg and the trial's lifestyle support on the same day, with no taper, and regained about two-thirds of the weight they had lost within a year (Wilding 2022); individual results vary, and its figures describe the 2.4 mg dose.
At GetLean we favour a gradual reduction under a doctor's guidance rather than a cliff-edge stop. Dr Quek steps the dose down at the monthly reviews, towards the lowest effective dose, and the daily WhatsApp coaching builds the eating pattern and the training habit while the medication is still working.
Coming off Wegovy walks through the weeks after the last dose. Weaning off GLP-1 explains how a planned taper works, how much weight comes back after stopping covers the two-thirds figure, and the coming-off guide brings the pieces together. Never stop or change a prescribed medicine on your own.
Designed to end: a programme whose pace and taper off the medication are planned from the first consult, so the result holds after the medication stops.
Common questions
Is Wegovy 7.2 mg available in Singapore?
It is in the registered label: the prescriber can increase the dose to 7.2 mg once weekly, if needed, after at least four weeks on 2.4 mg (NDF). Whether it is stocked is not stated in the sources read for this page, and whether it suits a person is the assessing doctor's decision.
How many injections is the 7.2 mg dose in Singapore?
Three. The label says to inject three doses of 2.4 mg one after the other (NDF). The US, UK and EU have a product made for 7.2 mg (FDA; Novo Nordisk report); none is on Singapore's register (HSA register).
How much weight did people lose on semaglutide 7.2 mg?
In STEP UP, a phase 3b trial of 1,407 adults without diabetes, weight change at 72 weeks was −18.7% on 7.2 mg, −15.6% on 2.4 mg and −3.9% on placebo (treatment-policy estimand) (Wharton 2025). Individual results vary and are not guaranteed.
I am already on Wegovy or Mounjaro with another doctor. Would 7.2 mg change anything?
It would change the dose and how it is given, with more stomach and gut events and more dysaesthesia than 2.4 mg in STEP UP (Wharton 2025). It would not change who decides: the medicine and dose are the prescribing doctor's choice. It says nothing about tirzepatide (Mounjaro).
What happens if I move to a new doctor while on a GLP-1 medication?
At GetLean, Dr Quek reviews a patient's history before anything changes, and suitability is decided at the consultation rather than by a number. Which medicine and dose, if any, follows from that review is his decision.
Does a higher dose change how treatment ends?
The reason for a planned exit does not depend on the dose. At GetLean the programme is designed to end, and Dr Quek steps the dose down at the monthly reviews rather than stopping it overnight. In the STEP 1 extension, semaglutide 2.4 mg was stopped overnight with no taper and about two-thirds of the lost weight returned within a year (Wilding 2022). Individual results vary.